High Expression of B7‑H2 or B7‑H3 is Associated with Poor Prognosis in Hepatocellular Carcinoma

Overview

Journal Mol Med Rep

Specialty Molecular Biology

Date 2019 Apr 4

PMID 30942404

Citations 22

Authors

Youshi Zheng

Naishun Liao

Yuan Wu

Ju Gao

Zhenli Li

Wenwen Liu

Yingchao Wang

Ming Li

Xiaolou Li

Li Chen

Wenmin Zhang

Bixing Zhao

Affiliations

Soon will be listed here.

Abstract

B7 family members have been associated with the signaling transduction pathways underlying tumor immune evasion in hepatocellular carcinoma. In the present study, associations between the clinical characteristics of patients with hepatocellular carcinoma (HCC) and the expression of B7‑H2 and B7‑H3 were analyzed. A total of 63 formalin‑fixed and paraffin‑embedded HCC tissues were collected to be used as a tissue microarray. Following this, the association between B7‑H2/B7‑H3 and the prognosis of patients with HCC was analyzed using Pearson's χ2 test, the Kaplan‑Meier method and receiver operating characteristic curve analysis. The results demonstrated that the expression of B7‑H2 was significantly associated with recurrence (within 1 year) in patients with HCC (P<0.01), and that the expression of B7‑H3 was associated with recurrence (within 1 year), metastasis and 2‑year overall survival rate in patients with HCC (P<0.01, P=0.036 and P=0.016, respectively). In addition, the combined expression of B7‑H2 and B7‑H3 was associated with prognostic factors, including recurrence (within 1 year) and survival rate (within 2 years), in patients with HCC. In particular, an increased area under the curve was achieved when the combined expression of B7‑H2 and B7‑H3 was considered, compared with that for α‑fetoprotein. Taken together, these results indicated that B7‑H2‑ and/or B7‑H3‑positive expression indicates a poor clinical outcome for patients, and the combination of B7‑H2 and B7‑H3 may be a preferential prognostic biomarker in patients with HCC.

Citing Articles

B7 homolog 3 in pancreatic cancer.

Perovic D, Dusanovic Pjevic M, Perovic V, Grk M, Rasic M, Milickovic M World J Gastroenterol. 2024; 30(31):3654-3667.

PMID: 39193002 PMC: 11346158. DOI: 10.3748/wjg.v30.i31.3654.

B7-H3 Expression in Breast Cancer and Brain Metastasis.

Joshi V, Beecher K, Lim M, Stacey A, Feng Y, Jat P Int J Mol Sci. 2024; 25(7).

PMID: 38612786 PMC: 11012592. DOI: 10.3390/ijms25073976.

Engaging stimulatory immune checkpoint interactions in the tumour immune microenvironment of primary liver cancers - how to push the gas after having released the brake.

Rakke Y, Buschow S, IJzermans J, Sprengers D Front Immunol. 2024; 15:1357333.

PMID: 38440738 PMC: 10910082. DOI: 10.3389/fimmu.2024.1357333.

New Emerging Targets in Cancer Immunotherapy: The Role of B7-H3.

Koumprentziotis I, Theocharopoulos C, Foteinou D, Angeli E, Anastasopoulou A, Gogas H Vaccines (Basel). 2024; 12(1).

PMID: 38250867 PMC: 10820813. DOI: 10.3390/vaccines12010054.

The prognostic value of a combined immune score in tumor and immune cells assessed by immunohistochemistry in triple-negative breast cancer.

Choi J, Lee J, Jin M, Nikas I, Kim K, Yang S Breast Cancer Res. 2023; 25(1):134.

PMID: 37924153 PMC: 10625207. DOI: 10.1186/s13058-023-01710-8.

References

Dong H, Zhu G, Tamada K, Chen L . B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999; 5(12):1365-9. DOI: 10.1038/70932. View

Jiang Y, Yang Z, Hu J . Recurrence or metastasis of HCC:predictors, early detection and experimental antiangiogenic therapy. World J Gastroenterol. 2002; 6(1):61-65. PMC: 4723599. DOI: 10.3748/wjg.v6.i1.61. View

Lee S, Hwang S, Jung J, Lee Y, Kim K, Ahn C . Outcome of patients with huge hepatocellular carcinoma after primary resection and treatment of recurrent lesions. Br J Surg. 2007; 94(3):320-6. DOI: 10.1002/bjs.5622. View

Liu C, Kao J . Hepatitis B virus-related hepatocellular carcinoma: epidemiology and pathogenic role of viral factors. J Chin Med Assoc. 2007; 70(4):141-5. DOI: 10.1016/S1726-4901(09)70346-6. View

Sumie S, Kawaguchi T, Komuta M, Kuromatsu R, Itano S, Okuda K . Significance of glucose intolerance and SHIP2 expression in hepatocellular carcinoma patients with HCV infection. Oncol Rep. 2007; 18(3):545-52. View

Choi G, Han D, Kim D, Choi S, Kang C, Kim K . Outcome after curative resection for a huge (>or=10 cm) hepatocellular carcinoma and prognostic significance of gross tumor classification. Am J Surg. 2009; 198(5):693-701. DOI: 10.1016/j.amjsurg.2008.09.019. View

Ng K, Yan T, Black D, Chu F, Morris D . Prognostic determinants for survival after resection/ablation of a large hepatocellular carcinoma. HPB (Oxford). 2009; 11(4):311-20. PMC: 2727084. DOI: 10.1111/j.1477-2574.2009.00044.x. View

Kang T, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D . Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature. 2011; 479(7374):547-51. DOI: 10.1038/nature10599. View

Forner A, Bruix J . Biomarkers for early diagnosis of hepatocellular carcinoma. Lancet Oncol. 2012; 13(8):750-1. DOI: 10.1016/S1470-2045(12)70271-1. View

10.

Braillon A . Hepatocellular carcinoma. Lancet. 2012; 380(9840):469. DOI: 10.1016/S0140-6736(12)61282-3. View

11.

Blachier M, Leleu H, Peck-Radosavljevic M, Valla D, Roudot-Thoraval F . The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013; 58(3):593-608. DOI: 10.1016/j.jhep.2012.12.005. View

12.

Chen W, Zheng R, Zhang S . Liver cancer incidence and mortality in China, 2009. Chin J Cancer. 2013; 32(4):162-9. PMC: 3845572. DOI: 10.5732/cjc.013.10027. View

13.

Vigdorovich V, Ramagopal U, Lazar-Molnar E, Sylvestre E, Lee J, Hofmeyer K . Structure and T cell inhibition properties of B7 family member, B7-H3. Structure. 2013; 21(5):707-17. PMC: 3998375. DOI: 10.1016/j.str.2013.03.003. View

14.

Pahwa A, Beckett K, Channual S, Tan N, Lu D, Raman S . Efficacy of the American Association for the Study of Liver Disease and Barcelona criteria for the diagnosis of hepatocellular carcinoma. Abdom Imaging. 2014; 39(4):753-60. DOI: 10.1007/s00261-014-0118-9. View

15.

Hwang M, Jayakrishnan T, Green D, George B, Thomas J, Groeschl R . Systematic review of outcomes of patients undergoing resection for colorectal liver metastases in the setting of extra hepatic disease. Eur J Cancer. 2014; 50(10):1747-1757. DOI: 10.1016/j.ejca.2014.03.277. View

16.

Xu B, Cai Z, Zeng Y, Chen L, Du X, Huang A . α-Methylacyl-CoA racemase (AMACR) serves as a prognostic biomarker for the early recurrence/metastasis of HCC. J Clin Pathol. 2014; 67(11):974-9. PMC: 4215266. DOI: 10.1136/jclinpath-2014-202378. View

17.

Leung J, Suh W . The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy. Immune Netw. 2015; 14(6):265-76. PMC: 4275384. DOI: 10.4110/in.2014.14.6.265. View

18.

Kang F, Wang L, Jia H, Li D, Li H, Zhang Y . B7-H3 promotes aggression and invasion of hepatocellular carcinoma by targeting epithelial-to-mesenchymal transition via JAK2/STAT3/Slug signaling pathway. Cancer Cell Int. 2015; 15:45. PMC: 4407415. DOI: 10.1186/s12935-015-0195-z. View

19.

Liu Y, Wang Y, Dingi G, Yang T, Jiang S, Wang L . Influence of surgical resection of hepatocellular carcinoma(HCC) for hematogenous dissemination of HCC cells and its effect on recurrence and metastasis: 3 years prospective study. Neoplasma. 2015; 62(4):635-40. DOI: 10.4149/neo_2015_076. View

20.

Hong B, Qian Y, Zhang H, Sang Y, Cheng L, Wang Q . Expression of B7-H4 and hepatitis B virus X in hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol. 2016; 22(18):4538-46. PMC: 4858635. DOI: 10.3748/wjg.v22.i18.4538. View